Abeona Therapeutics Inc.

Greetings. Welcome to the Abiona Therapeutics first quarter 23 portfolio update conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Greg Jin, Vice President of Investor Relations and Corporate Communications. You may begin.

Thank you, Holly.

Good morning, everyone. I would like to welcome and thank everyone for joining us on our Portfolio Update conference call. Our objective today is to share additional new positive data from our EB101 and AAV ophthalmology programs recently presented at scientific congresses. The press releases announcing the data at the ISID and ASGCT meetings are available on our website at www.abionatherapeutics.com. Before we start, I would like to note that remarks made during today's call may contain projections and forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are based on current expectations and are subject to change. and actual results may differ materially from those expressed or implied in the forward-looking statements. Various factors that could cause actual results to differ include, but are not limited to, those identified under the risk factor section in our Form 10-K and periodic reports filed with the SEC. These documents are available on our website at www.abionatherapeutics.com.